Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Prostate Cancer

Interventions

DRUG

ADT

Given by PO

DRUG

Enzalutamide

Given by PO

DRUG

Talazoparib

Given by PO

DRUG

Degarelix

Given PO or given INJ

DRUG

Luprolide

Given PO or given INJ

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT05873192 - Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | Biotech Hunter | Biotech Hunter